Targeting PAR-2 in atopic dermatitis: Preclinical evaluation of the novel inhibitor E6795

Area of Science:

• Dermatology
• Pharmacology
• Immunology

Background:

• Atopic dermatitis (AD) is a chronic inflammatory skin condition with persistent symptoms and treatment challenges.
• Protease-activated receptor 2 (PAR-2) is implicated in AD pathogenesis, driving inflammation, itch, and barrier disruption.
• Existing AD therapies offer insufficient control for many patients, necessitating novel treatment approaches.

Purpose of the Study:

• To evaluate E6795, a novel small-molecule PAR-2 inhibitor, as a potential therapeutic for atopic dermatitis.
• To assess the efficacy of E6795 in preclinical models of AD, focusing on inflammation, itch, and skin barrier function.
• To confirm the selectivity and safety profile of E6795 through kinase and pharmacological profiling.

Main Methods:

• Preclinical evaluation of E6795 in two distinct murine models of atopic dermatitis.
• Assessment of E6795's impact on inflammation, immune cell infiltration, and epidermal homeostasis.
• Measurement of transepidermal water loss (TEWL) and histological analysis of skin barrier integrity and pruritus.

Main Results:

• E6795 demonstrated selective inhibition of PAR-2 with minimal off-target effects.
• Oral and topical E6795 significantly reduced AD-related inflammation and immune cell infiltration in murine models.
• E6795 treatment improved skin barrier function, reduced TEWL, and alleviated pruritus.

Conclusions:

• E6795 effectively targets key pathophysiological mechanisms of AD, including barrier dysfunction, inflammation, and itch.
• The selective PAR-2 inhibition by E6795 offers a promising therapeutic strategy for atopic dermatitis.
• E6795 presents potential as a novel, cost-effective topical agent for AD, especially for treatment-refractory patients.